Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad

This strategic investment strengthens Cohance's integrated oligonucleotide platform

LAXAI Life Sciences appoints Sripathy Venkatraman as CEO

Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives

Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis

Morepen to launch new fatty lever drug ‘Resmetirom’

Thermo Fisher Scientific to invest $2 billion to expand US operation

Investment demonstrates confidence in America’s commitment to science and innovation

Suven Pharmaceuticals get final approval to amalgamate Cohance Lifesciences

The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services

Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s

Raichur site is the group’s largest API facility and part of a wider network of seven sites

Naturo & Orgo empowering brands through excellence

The company offers customized formulations tailored to align with each brand’s identity and consumer needs